REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Research/Paper
Back to Research Library
Semantic ScholarReview

Caffeine and SS-31 are Potential Treatments for Bardet-Biedl Syndrome via Improvement of Mitochondrial Function

Younes Rouabhi, D. Guo, Kamal Rahmouni
Physiology2025DOI: 10.1152/physiol.2025.40.s1.0655

Citations

0

Subjects

Non-Human

Study Context

Review papers consolidate the current state of knowledge on a topic. While they don't present new experimental data, they offer valuable context and identify gaps in existing research.

Citation

Younes Rouabhi, D. Guo, Kamal Rahmouni. (2025). Caffeine and SS-31 are Potential Treatments for Bardet-Biedl Syndrome via Improvement of Mitochondrial Function. Physiology. https://doi.org/10.1152/physiol.2025.40.s1.0655

This content is derived from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.